Phase 2CompletedAge-related condition

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

An Extension of Protocol NS-0100-01 to Evaluate the Safety and Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Mono-therapy on Glycemic Control in Subjects With Type 2 Diabetes

Sponsor
NuSirt Biopharma (Industry)
Enrollment
50 enrolled
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin; Mid Metformin; High Metformin; Metformin
Ages
adults, older adults
Registry
NCT02435277

Full record on ClinicalTrials.gov

From the registry

Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes using HbA1c as the primary endpoint.

Primary outcomes

  • Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started